Capstone Investment Advisors LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Capstone Investment Advisors LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 11,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $923,000.

Other large investors also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ANI Pharmaceuticals in the third quarter worth $32,992,000. Ranger Investment Management L.P. acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at $28,406,000. Deutsche Bank AG acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at $26,775,000. Balyasny Asset Management L.P. boosted its holdings in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. Finally, William Blair Investment Management LLC bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at $21,372,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 24,387 shares of company stock valued at $1,947,625. 8.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $105.83.

ANI Pharmaceuticals Trading Down 0.9%

Shares of ANIP stock opened at $72.83 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 15.70 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The firm has a fifty day moving average of $79.68 and a 200-day moving average of $78.65.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.